We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Prevention of Neutropenia After Using G-CSF With TAC Chemotherapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01571518
Recruitment Status : Unknown
Verified April 2012 by Hyuk moon Kim, Sunchonhang University.
Recruitment status was:  Not yet recruiting
First Posted : April 5, 2012
Last Update Posted : April 5, 2012
Dong-A Pharmaceutical Co., Ltd.
Information provided by (Responsible Party):
Hyuk moon Kim, Sunchonhang University

Brief Summary:
After resection of lymph node positive breast cancer, the injection duration and timing of Granulocyte-colony stimulating factor (G-CSF) could affect the neutropenia with TAC (Taxotere, Adriamycin, cyclophosphamide) chemotherapy.

Condition or disease Intervention/treatment Phase
Neutropenia Drug: late leukostim Drug: early leukostim Phase 4

Detailed Description:
The duration and the injection timing of G-CSF are effective in the prevention of neutropenia, incidence of infection and non hematologic toxicity. With the TAC chemotherapy after resection of breast cancer, the G-CSF early injection versus late injection could change the frequency of neutropenia.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Optimal Timing and Duration of Daily G-CSF With Adjuvant TAC Chemotherapy in Node-positive Breast Cancer;Multicenter, Randomized, Open Label, Clinically IV Phase
Study Start Date : April 2012
Estimated Primary Completion Date : October 2013
Estimated Study Completion Date : October 2013

Arm Intervention/treatment
Experimental: early injection
injection of G-CSF (leukostim)5㎍/kg from day 2 of TAC chemotherapy
Drug: late leukostim
injection of G-CSF (leukostim)5㎍/kg from day 5 of TAC chemotherapy
Other Name: 5leuko

Sham Comparator: late injection
injection of G-CSF (leukostim)5㎍/kg from day 5 of TAC chemotherapy
Drug: early leukostim
injection of G-CSF (leukostim)5㎍/kg from day 2 of TAC chemotherapy
Other Name: 2leuko

Primary Outcome Measures :
  1. frequency of neutropenia [ Time Frame: Change from Baseline in neutrophil count at 21days ]
    during the 1 cycle (21days) of ajuvant chemotherapy with TAC, record the frequency of neutropenia aftr using G-CSF (Leucostim)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   20 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • primary invasive breast carcinoma with lymph node positive with curative surgery with TAC chemotherapy

Exclusion Criteria:

  • pregnancy,
  • cardiovascualr disease,
  • abnormal renal function,
  • hematologic disorder

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01571518

Layout table for location contacts
Contact: Chul Wan Lim, M.D., Ph.D 82-32-621-5114 cylim@soonchunhyang.com

Layout table for location information
Korea, Republic of
Soonchunhyang university Puchun Hospital
Puchun, Korea, Republic of
Contact: Hyuk moon Kim, MD    82-32-621-5114    hmkim@soonchunhyang.com   
Principal Investigator: ChulWan Lim, MD.PhD         
Sponsors and Collaborators
Hyuk moon Kim
Dong-A Pharmaceutical Co., Ltd.
Layout table for investigator information
Study Chair: Chul Wan Lim, MD,PhD Soonchunhyang U Puchun Hospital
Publications of Results:
Layout table for additonal information
Responsible Party: Hyuk moon Kim, Assistant professor, Sunchonhang University
ClinicalTrials.gov Identifier: NCT01571518    
Other Study ID Numbers: 2011-91
First Posted: April 5, 2012    Key Record Dates
Last Update Posted: April 5, 2012
Last Verified: April 2012
Keywords provided by Hyuk moon Kim, Sunchonhang University:
Additional relevant MeSH terms:
Layout table for MeSH terms
Leukocyte Disorders
Hematologic Diseases